Velocity Clinical Research Expands Executive Team With Appointment Of Drew Reina As Chief Revenue Officer To Advance Strategic Partnerships And Business Growth

Velocity Clinical Research, a leading fully integrated clinical site organization, announced the appointment of Andrew (Drew) Reina as Chief Revenue Officer (CRO), effective immediately. Drew joins Velocity from Fortrea, one of the world’s leading contract research organizations (CROs), where he held senior leadership positions focused on driving growth strategies and global business development.

This appointment marks a significant milestone in Velocity’s continued evolution as the company works to redefine strategic collaboration between multisite clinical research corporations (MCRCs), Sponsors, and CRO partners. In his new role, Drew will oversee Velocity’s revenue generation and partnership strategy, ensuring alignment between patient recruitment expectations and strategic delivery for biotechnology firms, large pharmaceutical companies, and small to mid-sized Sponsors and CROs.

Commenting on the appointment, Paul Evans, PhD, President and Chief Executive Officer of Velocity, stated, “This has been a challenging year for the clinical research industry in many ways. Andrew’s experience at Fortrea brings valuable CRO-focused leadership to our executive team. His appointment is a key step toward strengthening Velocity’s position not just as a leading site network, but as a strategic partner uniquely equipped to meet the evolving needs of biotech and pharmaceutical companies.”

Drew Reina shared his enthusiasm about joining Velocity, saying, “I’m honored to be part of this exceptional team. Velocity has established itself as a benchmark for what it means to be a truly integrated site network, known for its quality, scale, and operational excellence in clinical research. These attributes are vital as the industry faces increasing complexity in clinical trial execution. Today, Sponsors and CROs are relying more than ever on MCRCs to accelerate speed to market and ease the burden on both sites and patients. Velocity is uniquely positioned to meet these challenges, and I’m excited to contribute to its continued growth and impact.”

Drew brings more than 20 years of global experience in clinical research and commercial leadership. Before joining Velocity, he served as Vice President and Head of Sales at Fortrea (formerly Labcorp Drug Development), where he led a high-performing commercial organization, developed strategic partnerships, and supported the execution of Phase 1–4 clinical trials across therapeutic areas. Prior to Fortrea, he held the position of Vice President for PPD’s Biopharma segment, where he managed a global portfolio exceeding $1 billion and oversaw Phase 2–4 studies, strategic alliances, and partnership management.

Drew holds a degree in Finance from George Mason University’s School of Management and an MBA from INSEAD. Throughout his career, he has built a reputation for establishing strong enterprise-level partnerships with global Sponsors, scaling operational capabilities, and optimizing site networks for improved speed, quality, and cost efficiency.

As part of Velocity’s executive leadership team, Drew will be responsible for driving sustainable growth through strategic partnerships with Sponsors and CROs. He will also work closely with the Chief Operating Officer to ensure that business development, marketing, and site network operations are aligned, supporting superior trial feasibility, patient recruitment, and overall performance to meet Sponsor and CRO expectations.